n intrauterine device (IUD) is a reversible, cost-effective contraception method with low complication rates. 1 The incidence of uterus perforation of an IUD is 1-3 per 1000 insertions. 2 However, transvesical migration of an IUD is very rare. We present the diagnosis and treatment of a patient who had an IUD inserted 12 years earlier and presented with urinary symptoms after bladder migration of the IUD and stone formation.
CASE REPORT
A 34-year-old woman presented with a history of recurrent urinary tract infections, suprapubic and pelvic pain, dysuria, and gross hematuria. She had recurrent symptoms year-round. Urinalysis revealed inflammation. The complete blood count and blood biochemistry profile were within normal levels. A plain abdominal radiograph revealed a stone and metallic foreign Cystoscopy performed under general anesthesia confirmed the intravesical stone. Pneumatic lithotripsy was performed, and the migrated IUD was identified (Figure 3) . The IUD penetrated the bladder mucosa and a bladder stone formed around the IUD. The IUD was grasped with forceps and gently extracted through the cystoscope (Figure 4) . Then, cystography was performed. There was no fistula between the bladder and uterus. A Foley catheter was left in bladder for 1 day postoperatively. The patient was discharged the day after the surgery without any complications.
DISCUSSION
Although the reason for the uterine perforation and migration of an IUD is not clear, the complication rate varies with the size and shape of the IUD, genital infections, position of the uterus and experience of the clinician who inserted the IUD. The time of IUD placement, uterine congenital anomalies, and past surgery all increase the risk of uterine perforation. 3 While uterine perforation typically occurs during insertion, migration to the bladder and symptom improvement progress slowly. 4 The IUD in our patient had been inserted by a non-physician after a pregnancy, and the "lost" IUD wasn't investigated thoroughly.
In cases of a lost IUD, the symptoms vary with the location. An IUD may pass through the uterine wall into the gynecological, urinary or gastrointestinal organs. In such cases, micturition functions should be investigated and intravesical migration kept in mind. There may be secondary stone formation around the IUD after migration to the bladder. Clinicians should consider the possibility of foreign bodies whenever there is a bladder stone found in a woman. In our case, there was a history of continuous antibiotic use to treat recurrent urinary tract infections for years, dysuria, and suprapubic pain. Despite these repetitive symptoms and treatment, the patient had not been consulted to an urologist.
An IUD that cannot be found on vaginal examination requires careful follow-up. A plain pelvic x-ray should be obtained first to clarify whether the lost IUD is located in the pelvis. Abdominopelvic ultrasound is also very useful for determining the location of an IUD. 5 In some cases, pelvic CT is necessary for a diagnosis. 6 Our case was diagnosed by pelvic CT after detecting opacities suggestive of a stone and foreign body in the pelvis on plain x-rays.
The standard treatments for IUD migration to the bladder are minimally invasive. 7 Endoscopic extraction of a total intravesical IUD encrusted with calculi is the treatment of choice, with high success rates and low complication and morbidity rates. 8 In this case, cystoscopic removal was successful. With large stones or with genitourinary fistula that cannot be extracted by endoscopic methods and an IUD that has only partially migrated to the bladder, open surgery or minimally invasive laparoscopic methods can be performed. 9, 10 When investigating patients with a lost IUD complaining of micturition symptoms, chronic pelvic pain, or recurrent urinary tract infections, bladder migration of the IUD should be kept in mind. An endoscopic approach is the first treatment option.
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